INTRODUCTION {#s1}
============

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide \[[@R1]--[@R3]\]. About 745,000 deaths per year can be attributed to HCC \[[@R4]\]. Hepatic resection is currently the most optimal choice for HCC treatment. However, surgical resection is not applicable in most patients, and its long-term prognosis remains unsatisfactory \[[@R5]\]. To date, it is known that both cellular changes and etiological agents (i.e., virus infection and alcohol) are responsible for the cause of HCC \[[@R6], [@R7]\]. However, like any other complex diseases \[[@R8]\], the molecular pathogenesis of HCC remains poorly understood \[[@R9]\]. The lack of good diagnostic markers and therapeutic targets has rendered HCC a major challenge.

Recently, with dramatically increased throughput, next-generation sequencing provides an efficient tool to illustrate the transcriptome characteristics of cancers, including HCC. Transcriptome sequencing has been used to identify latent biomarkers for HCC \[[@R10]--[@R12]\], implicating its great potential in exploring the molecular basis of HCC. Of note, by using transcriptome sequencing, a recurrent chimeric transcript *DNAJB1-PRKACA* \[[@R13]\] was identified in fibrolamellar HCC (FL-HCC) patients, suggesting that this fusion transcript contributes to the pathogenesis of the FL-HCC and may represent a therapeutic target. Therefore, transcriptome sequencing is a revolutionary tool to investigate the cancer transcriptome and identify possible therapeutic targets \[[@R14]\].

In this study, we performed transcriptome sequencing for HCC and adjacent non-tumorous tissues to investigate the molecular basis of HCC. Nine patients diagnosed as primary HCC were recruited and differentially expressed genes (DEGs) were identified. Candidate fusion transcripts were also identified by using defuse \[[@R15]\]. Further RT-PCR and Sanger sequencing experiments were performed to validate potential recurrent fusion transcripts in other 54 pairs of tumor and adjacent non-tumor samples. Our investigation may shed light on the molecular event responsible for the progression of HCC and offer new possibilities for clinical management of HCC patients.

RESULTS {#s2}
=======

Overview of transcriptome sequencing statistics {#s2_1}
-----------------------------------------------

Pair-end second-generation transcriptome sequencing was performed in nine HCC patients. Sample characteristics are list in Table [1](#T1){ref-type="table"}. An average of 35,772,695 pair-end 125 bp clean reads was generated (Table [2](#T2){ref-type="table"}). The average mapping rate was 93.17%, resulting an average coverage of depth of 32x (Table [2](#T2){ref-type="table"}).

###### Sample characteristics

  Patient     Age        Gender    Hepatitis   Serum AFP level(ng/mL)   Metastasis   Glisson capsule invasion   Tumor size (mm)   Multiple liver nodules
  ----------- ---------- --------- ----------- ------------------------ ------------ -------------------------- ----------------- ------------------------
  ***P10***   ***59***   ***M***   ***HBV***   ***670.10***             ***No***     ***--***                   ***35***          ***-***
  **P14**     **50**     **M**     **HBV**     **12483**                **No**       **+**                      **50**            **-**
  **P17**     **37**     **M**     **HBV**     **4.47**                 **No**       **+**                      **41**            **-**
  **P21**     **62**     **M**     **HBV**     **266.5**                **No**       **+**                      **32**            **-**
  **P24**     **76**     **M**     **HCV**     **5.84**                 **No**       **+**                      **70**            **-**
  **P26**     **59**     **M**     **HBV**     **3.73**                 **No**       ***--***                   **6**             **-**
  **P29**     **69**     **M**     **HBV**     **6.90**                 **No**       **+**                      **160**           **synchronous**
  **P36**     **61**     **M**     **NBNC**    **1.11**                 **No**       **+**                      **80**            **-**
  **P40**     **19**     **F**     **NBNC**    **2.85**                 **No**       ***--***                   **29**            **-**
  *L24*       *63*       *M*       *HBV*       *2975*                   *No*         *+*                        *70*              *synchronous*
  *L26*       *47*       *M*       *HBV*       *5375*                   *Yes*        *+*                        *130*             *-*
  *L44*       *72*       *M*       *HBV*       *303.8*                  *No*         *+*                        *40*              *synchronous*
  *L134*      *66*       *M*       *HBV*       *60500*                  *No*         *+*                        *50*              *-*
  *H19*       *59*       *M*       *NBNC*      *54.84*                  *No*         *+*                        *26*              *-*
  L6          48         M         NBNC        55.1                     Yes          \+                         180               \-
  L21         41         M         HBV         4.70                     Yes          \+                         50                \-
  L25         72         M         HBV         1110                     No           \+                         80                \-
  L30         50         M         HBV         260.9                    No           ***--***                   25                \-
  L36         64         M         HBV         244.6                    Yes          \+                         65                synchronous
  L39         67         M         HBV         321.1                    No           \+                         55                synchronous
  L45         71         M         HBV         4606                     Yes          \+                         12                \-
  L46         18         F         HBV         37979                    No           \+                         70                \-
  L49         45         M         HBV         6528                     No           \+                         60                synchronous
  L52         50         M         HBV         3.03                     Yes          \+                         55                synchronous
  L53         61         M         HBV         1.90                     No           \+                         30                \-
  L54         52         M         HBV         26.53                    No           \+                         20                \-
  L55         55         M         HBV         1.82                     No           \+                         34                \-
  L57         58         F         HBV         2.55                     Yes          \+                         55                synchronous
  L61         42         M         HBV         3.38                     No           \+                         20                synchronous
  L64         64         M         HBV         774.2                    No           \+                         10                \-
  L68         54         F         NBNC        23784                    No           \+                         22                \-
  L72         40         M         HBV         1816                     No           \+                         30                \-
  L73         74         M         NBNC        5.90                     No           \+                         30                \-
  L85         76         M         NBNC        2.10                     No           \+                         34                \-
  L154        47         M         HBV         62.47                    Yes          \+                         105               \-
  L195        67         M         NBNC        3.01                     Yes          \+                         80                \-
  H1          37         M         HBV         1810                     No           ***--***                   55                \-
  H2          67         M         HBV         3103                     No           \+                         40                \-
  H3          48         M         HBV         2.07                     No           ***--***                   35                \-
  H4          68         M         HBV         15.87                    No           \+                         35                \-
  H5          71         M         HBV         11.65                    No           \+                         35                \-
  H6          56         M         HBV         33571                    No           \+                         57                \-
  H7          52         M         HBV         2100                     Yes          ***--***                   35                \-
  H8          52         M         NBNC        5.30                     No           \+                         65                \-
  H9          37         M         HBV         \>60500                  Yes          ***--***                   95                \-
  H11         46         M         HBV         4.64                     No           ***--***                   45                \-
  H13         52         F         NBNC        2.45                     No           \+                         22                \-
  H16         75         M         NBNC        4.14                     Yes          \+                         87                synchronous
  H22         47         M         HBV         5.78                     No           \+                         40                \-
  H25         60         M         HBV         61.54                    No           ***--***                   25                \-
  H27         65         M         HBV         5.34                     No           \+                         70                \-
  H28         63         M         HBV         3396                     No           \+                         40                \-
  H29         52         M         HBV         66.50                    No           \+                         22                \-
  H30         58         M         HBV         6.52                     Yes          \+                         58                synchronous
  H31         42         M         HBV         3.31                     No           \+                         30                \-
  H32         62         M         HBV         570                      No           \+                         28                \-
  H33         46         M         HBV         3780                     No           \+                         21                synchronous
  H34         64         M         HBV         36541                    Yes          \+                         140               \-
  H35         47         F         HCV         250.5                    No           ***--***                   22                \-
  H36         39         M         HBV         8.10                     Yes          \+                         22                synchronous
  H37         63         M         HBV         208                      No           \+                         40                \-
  H38         48         M         NBNC        3.07                     No           \+                         33                \-
  H39         66         M         HBV         82.81                    No           \+                         34                \-

Note: The nine samples used for sequencing are shown in bold. The six samples with validated fusion *CRYL1*-*IFT88* are shown in italic.

###### Summary statistics of the transcriptome sequencing

  Patient   Sample type   Total reads   Mapped reads     Total base (bp)   Mapped base (bp)   Mappping ratio   Coverage (X)
  --------- ------------- ------------- ---------------- ----------------- ------------------ ---------------- --------------
  P10       T             35,930,408    33,819,287       4,491,301,000     4,227,410,875      94.12%           33
  N         34,902,228    32,863,973    4,362,778,500    4,107,996,625     94.16%             32               
  P14       T             35,315,378    33,125,921       4,414,422,250     4,140,740,125      93.80%           32
  N         34,383,802    32,279,443    4,297,975,250    4,034,930,375     93.88%             31               
  P17       T             35,532,658    33,258,212       4,441,582,250     4,157,276,500      93.60%           32
  N         34,537,914    32,152,860    4,317,239,250    4,019,107,500     93.09%             31               
  P21       T             34,762,386    32,701,011       4,345,298,250     4,087,626,375      94.07%           31
  N         35,314,918    33,021,170    4,414,364,750    4,127,646,250     93.50%             32               
  P24       T             35,610,444    32,509,118       4,451,305,500     4,063,639,750      91.29%           31
  N         34,637,398    31,280,461    4,329,674,750    3,910,057,625     90.31%             30               
  P26       T             34,566,526    32,670,216       4,320,815,750     4,083,777,000      94.51%           31
  N         35,384,486    33,407,169    4,423,060,750    4,175,896,125     94.41%             32               
  P29       T             34,564,642    32,385,294       4,320,580,250     4,048,161,750      93.69%           31
  N         34,771,048    32,792,475    4,346,381,000    4,099,059,375     94.31%             32               
  P36       T             35,371,920    32,571,695       4,421,490,000     4,071,461,875      92.08%           31
  N         35,959,532    32,990,753    4,494,941,500    4,123,844,125     91.74%             32               
  P40       T             42,279,434    39,097,967       5,284,929,250     4,887,245,875      92.50%           38
  N         40,083,384    36,852,292    5,010,423,000    4,606,536,500     91.90%             35               
  Average   35,772,695    33,321,073    4,471,586,847    4,165,134,146     93.17%             32               
  Total     643,908,506   599,779,317   80,488,563,250   74,972,414,625                                        

DEGs analyses results {#s2_2}
---------------------

We next detected DEGs between tumor and non-tumor samples. A total of 1943 DEGs were detected, including 690 up-regulated and 1253 down-regulated genes.

DEGs were subjected to KEGG pathway analyses. As shown in Table [3](#T3){ref-type="table"}, with the cut off of FDR \< 0.05, DEGs were enriched in ten pathways, including cell cycle (hsa04110), DNA replication (hsa03030), p53 (hsa04115) and complement and coagulation cascades pathway (hsa04610), as well as retinol, xenobiotics by cytochrome P450, drug, arachidonic acid, tyrosine and fatty acid metabolism pathway (hsa00830, 00980, 00982, 00590, 00350, 00071). The GO category enrichment analyses resulted extensive items overrepresented with DEGs. As shown in Table [3](#T3){ref-type="table"}, GO items (FDR \< 10^--3^) enriched with DEGs were associated with cell cycle and other processes, such as immune response, DNA replication, complement activation, oxidation, metabolism, and so on.

###### KEGG pathway and gene ontology biological process items enrichment analyses result for the DEGs

  Term                                                                 DEG Count   FDR
  -------------------------------------------------------------------- ----------- -----------------
  KEGG pathway                                                                     
  hsa04110:Cell cycle                                                  31          6.10 × 10^--6^
  hsa00830:Retinol metabolism                                          17          1.82 × 10^--4^
  hsa00980:Metabolism of xenobiotics by cytochrome P450                17          7.69 × 10^--4^
  hsa03030:DNA replication                                             12          2.97 × 10^--3^
  hsa00982:Drug metabolism                                             16          4.21 × 10^--3^
  hsa04610:Complement and coagulation cascades                         15          9.85 × 10^--3^
  hsa00590:Arachidonic acid metabolism                                 13          1.03 × 10^--2^
  hsa00350:Tyrosine metabolism                                         11          3.96 × 10^--2^
  hsa00071: Fatty acid metabolism                                      10          4.17 × 10^--2^
  hsa04115:p53 signaling pathway                                       13          4.58 × 10^--2^
  GO item                                                                          
  GO:0022403\~cell cycle phase                                         84          5.15 × 10^--16^
  GO:0000278\~mitotic cell cycle                                       77          4.11 × 10^--15^
  GO:0000279\~M phase                                                  70          3.45 × 10^--14^
  GO:0007067\~mitosis                                                  54          1.87 × 10^--13^
  GO:0000280\~nuclear division                                         54          1.87 × 10^--13^
  GO:0048285\~organelle fission                                        55          2.72 × 10^--13^
  GO:0000087\~M phase of mitotic cell cycle                            54          4.11 × 10^--13^
  GO:0007049\~cell cycle                                               118         1.26 × 10^--12^
  GO:0022402\~cell cycle process                                       94          3.43 × 10^--12^
  GO:0009611\~response to wounding                                     87          6.60 × 10^--11^
  GO:0006954\~inflammatory response                                    61          7.36 × 10^--10^
  GO:0051301\~cell division                                            57          1.09 × 10^--9^
  GO:0007059\~chromosome segregation                                   26          8.40 × 10^--9^
  GO:0006952\~defense response                                         90          1.38 × 10^--8^
  GO:0006955\~immune response                                          97          2.41 × 10^--8^
  GO:0051726\~regulation of cell cycle                                 53          4.06 × 10^--6^
  GO:0006260\~DNA replication                                          36          9.33 × 10^--6^
  GO:0002526\~acute inflammatory response                              24          1.13 × 10^--5^
  GO:0002253\~activation of immune response                            23          2.07 × 10^--5^
  GO:0050778\~positive regulation of immune response                   29          4.88 × 10^--5^
  GO:0007051\~spindle organization                                     15          5.21 × 10^--5^
  GO:0031960\~response to corticosteroid stimulus                      21          5.78 × 10^--5^
  GO:0051384\~response to glucocorticoid stimulus                      20          5.84 × 10^--5^
  GO:0048545\~response to steroid hormone stimulus                     34          9.52 × 10^--5^
  GO:0055114\~oxidation reduction                                      79          1.70 × 10^--4^
  GO:0010033\~response to organic substance                            86          2.60 × 10^--4^
  GO:0002684\~positive regulation of immune system process             38          2.84 × 10^--4^
  GO:0002252\~immune effector process                                  26          3.08 × 10^--4^
  GO:0051329\~interphase of mitotic cell cycle                         22          3.60 × 10^--4^
  GO:0045087\~innate immune response                                   26          5.19 × 10^--4^
  GO:0000079\~regulation of cyclin-dependent protein kinase activity   15          5.37 × 10^--4^
  GO:0000226\~microtubule cytoskeleton organization                    27          5.58 × 10^--4^
  GO:0051325\~interphase                                               22          5.67 × 10^--4^
  GO:0006956\~complement activation                                    13          6.96 × 10^--4^
  GO:0008203\~cholesterol metabolic process                            20          7.33 × 10^--4^
  GO:0000070\~mitotic sister chromatid segregation                     12          7.35 × 10^--4^
  GO:0009719\~response to endogenous stimulus                          54          7.58 × 10^--4^
  GO:0000819\~sister chromatid segregation                             12          9.75 × 10^--4^

Fusion genes detection and validation {#s2_3}
-------------------------------------

To detect fusion transcripts that might be the potential cause for tumorigenesis, the software defuse was used and after the filtering process as described in the methods section. Seven candidate fusion genes were detected (Table [4](#T4){ref-type="table"}). Using RT-PCR and Sanger sequencing, the fusion gene *CRYL1*-*IFT88* was successfully validated in the discovery sequencing sample (P10 tumor sample) and it was also validated in another 5 tumor samples (Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). Therefore, this fusion gene is considered as a recurrent fusion transcript related to HCC with the recurrent rate of about 9.52% (6/63). To investigate how the gene fusion *CRYL1*-*IFT88* affected their expression and proteins, we observed the reads coverage in genomes by IGV (Integrative Genomics Viewer) and domains by NCBI CD-search (Conserved Domains search). We found that quite a lot RNA-Seq reads covered in the intron between exon 15 and exon 16 of *IFT88* in tumor sample of P10, but this was not observed in the matched normal sample (Figure [3](#F3){ref-type="fig"} top), which indicated that the transcription structure of *IFT88* was very likely changed in the tumor cells with this fusion. This break was just occurred in the middle of IFT88 protein sequence ((Figure [3](#F3){ref-type="fig"} bottom), which might totally destroy the function of IFT88. However, the change of reads coverage was not observed in the genes *CRYL1*, it might be the high expression of wild-type *CRYL1* masked the change of expression structure.

###### Information of the identified fusion genes

  Sample id   Sample type   Gene1-Gene2        Break point1     Break point2     Break point1 location   Break point2 location
  ----------- ------------- ------------------ ---------------- ---------------- ----------------------- -----------------------
  P10         tumor         *CRYL1*-*IFT88*    chr13:21063509   chr13:21184715   coding                  intron
  P14         tumor         *BRD9-OR4*N2       chr5:886707      chr14:20230047   coding                  5′-UTR
  P14         tumor         *MPV17*-*TRIM54*   chr2:27545315    chr2:27527827    coding                  coding
  P24         tumor         *BHMT-MTATP6P1*    chr5:78427385    chr1:569753      3′-UTR                  exon
  P26         tumor         *NOMO3-XYLT1*      chr16:16372646   chr16:17323802   coding                  intron
  P26         tumor         *NOMO3-XYLT1*      chr16:16372646   chr16:17318037   coding                  intron
  P29         tumor         *TNFSF14-C3*       chr19:6664861    chr19:6677181    3′-UTR                  downstream

![Detection and Sanger sequencing validation of a recurrent fusion transcript *CRYL1-IFT88*\
(**A**) Illustration of the *CRYL1*-*IFT88* fusion gene (top) and Sanger sequencing validation result for the transcriptome tumor sequencing sample (P10) (bottom). (**B**) Sanger sequencing validation result for the other five tumor samples. The IDs of samples corresponded to Table [1](#T1){ref-type="table"}. The fusion point was marked with dash line.](oncotarget-08-40693-g001){#F1}

![The agarose gel electrophoresis of the six samples with successfully validated fusion transcript *CRYL1-IFT88*\
The RT-PCR product for the fusion gene was 230 bp. The IDs of samples corresponded to Table [1](#T1){ref-type="table"}. T and N represented tumor and adjacent non-tumor tissue, respectively.](oncotarget-08-40693-g002){#F2}

![The RNA-Seq reads coverage and functional domains of IFT88\
The RNA-Seq reads coverage of gene *IFT88* by IGV in the samples of patient P10 was shown at the top, and the functional domains of IFT88 according to NCBI CD-search was shown at the bottom. The red dotted line indicated the breakpoint.](oncotarget-08-40693-g003){#F3}

To discover the function of the fusion transcript, we performed both 3′ and 5′ RACE (rapid-amplification of cDNA ends) experiments and obtained the full-length *CRYL1-IFT88* fusion sequence (779 bp). The longest ORF was 279 bp (predicted by NCBI ORF-finder) and corresponding to a 92 aa protein sequence (see [Supplementary File.docx](#SD1){ref-type="supplementary-material"}). And the fusion protein contained most of the domain of CRYL1, including 3-hydroxybutyryl-CoA dehydrogenase domain, NAD binding domain, and so on, which indicated that the functional of the CRYL1-IFT88 were similar with CRYL1 (see [Supplementary File.docx](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

We have applied the transcriptome sequencing approach to illustrate the gene expression characteristics of HCC. Pathway analyses showed that ten pathways, including cell cycle, DNA replication, p53 and complement and coagulation cascades as well as six metabolism processes, were overrepresented with DEGs. Deregulation of the cell cycle \[[@R16]\], DNA replication \[[@R17]\] and p53 pathways \[[@R18]\] are expected since uncontrolled cell division and aberrant tumor suppressor are the major character of cancer cells. As for the complement and coagulation cascades pathway, consistent with our results, both gene expression \[[@R19]\] and proteomics \[[@R20]\] analyses have shown that this pathway is related to the pathogenesis of HCC.

Gene fusion is an important event involved in the development of various types of malignancies, which is the consequence of the genomic rearrangements with a deletion, insertion, translocation or inversion of distal intra- or inter-chromosomal sequences \[[@R21]\]. The oncogenic activation may be triggered by the gene activation or repression due to gene fusion. The Philadelphia chromosome found in chronic myelogenous leukemia (CML) consisting of the BCR-ABL fusion gene is a classical example of gene fusion, an activated tyrosine kinase that drives CML \[[@R22]\]. Recent technology advances especially transcriptome sequencing and bioinformatics strategy for processing cancer profiling data, make the discovery of more fusion genes in cancers, including a recurrent chimeric transcript *DNAJB1-PRKACA* in FL-HCC \[[@R9]\] and *SLC45A3-ELK4* in prostate cancers \[[@R23]\], etc. These known fusion genes provide key insights into tumor biology and have significant clinical impact by serving as potential diagnostic markers or therapeutic targets. In our study, we detected seven chimeric transcripts in total by transcriptome sequencing. Fusion genes were subjected to validation and successfully confirmed that *CRYL1*-*IFT88* is a recurrent fusion transcript related with HCC. To our knowledge, this fusion gene was first reported and validated in HCC. Protein encoded by *CRYL1* catalyzes the dehydrogenation of L-gulonate into dehydro-L-gulonate in the uronate cycle, which is an alternative glucose metabolic pathway. Reduced expression of *CRYL1* in HCC has been observed in many studies \[[@R24]--[@R26]\]. Moreover, it was reported that reduced *CRYL1* expression in HCC confers cell growth advantages and correlates with adverse patient prognosis \[[@R26]\]. Protein encoded by *IFT88* is a member of the tetratrico peptide repeat (TPR) family, and is involved in liver oval cell proliferation, differentiation, and ploidy control \[[@R27]\]. Tumor suppression activity of this gene was demonstrated and this gene was reported as a liver neoplasia tumor suppressor gene in a previous study \[[@R28]\]. According to our bioinformatics analysis, the protein function of IFT88 might be suppressed due to the gene fusion. Considering the potential involvement of these two genes in HCC, the fusion transcript we identified here might be responsible for the tumorigenesis and serve as potential targets for further therapeutic strategy by the overexpression of *IFT88* to overcome the function inhibition due to gene fusion *CRYL1-IFT88*.

In conclusion, we used transcriptome sequencing approach to illustrate the gene expression characteristics of HCC. Cell cycle, DNA replication, p53 and complement and coagulation cascades pathways as well as some metabolism processes were overrepresented with DEGs. Of note, we detected and successfully validated *CRYL1*-*IFT88* as a recurrent fusion transcript in HCC with the recurrent rate of about 9.52% (6/63).

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

Our study design was approved by the institutional review board of the Fujian provincial hospital. Written informed consent was obtained from all subjects.

Subjects {#s4_2}
--------

Sixty-three subjects aged from 18 to 76 were diagnosed as primary HCC in the Fujian provincial hospital during the period from 03/01/2014 to 12/31/2015. Hepatitis B virus (HBV) related tumors were defined according to the presence of HB surface antigen (HBsAg) in serum, and hepatitis C virus (HCV) related tumors were according to the presence of antibody to HCV (HCVAb) in serum. NBNC tumor was defined according to the absence of both HBsAg and HCVAb in serum. Primary tumor and adjacent non-tumorous samples were obtained from all patients who underwent surgical tumor resection. All samples were frozen immediately at --80°C until RNA extraction. Total RNA was isolated by using RecoverAll™ Total Nucleic Acid Isolation Kit (Life Technologies, Carlsbad, CA, USA). Integrity of RNA was assessed by Agilent 2100 bioanalyzer (Agilent, Santa Clara, CA, USA). RNA from nine samples was subjected to sequencing and other samples were used in the validation experiments.

Transcriptome sequencing {#s4_3}
------------------------

Sequencing libraries were prepared by using prepared by using TruSeq RNA Sample Prep Kit (Illumina, San Diego, CA, USA) according to standard protocols. Briefly, total RNA was firstly randomly fragmented and poly-A-selected. Secondly, the RNA fragments were reverse transcribed to cDNA, end-repaired and ligated with adapters. The libraries then underwent size selection, PCR and purification. The quality of libraries was assessed by using Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA). Sequencing was then performed on an Illumina HiSeq 2500 sequencer with 125 bp pair-end reads. All raw data have been deposited in the NIH Short Read Archive database (Access number: SRP 102722).

Reads processing {#s4_4}
----------------

Raw sequencing reads were firstly filtered for adapters and ribosomal RNA. Reads containing five or more low quality (quality score \< 20) bases were also removed. The remained high-quality reads were then aligned to human genome (hg19) by using Tophat \[[@R29]\]. The mapped reads were then subjected to alignment against the the human transcriptome (Ensembl, GRCh37.73). Gene expression level measured by FPKM (fragments per kilobase per million) was calculated by Cufflinks \[[@R30]\]. All processed expression data have been submitted to GEO database (Access number: GSE 97214).

Differentially expressed genes (DEGs) analysis {#s4_5}
----------------------------------------------

For each group, DEGs between the tumor and matched non-tumor tissues were selected with pair-wise *t* test and the significant threshold was set as *p-value* of less than 0.05 and \|log~2~(fold change, FC)\| \> = 1. DAVID \[[@R31]\] was used to do the Gene Ontology (GO) and KEGG pathway annotation and enrichment analyses. The significant threshold for enrichment was set as false discovery rate (FDR) \< 0.05.

Fusion gene detection {#s4_6}
---------------------

Fusion transcripts were identified by defuse \[[@R15]\]. The default filtering processes of defuse were carried out as previously described \[[@R15]\]. The results of deFuse were further filtered to reduce false positives with the following criteria: 1) predictions supported by less than eight reads were removed; 2) predictions between adjacent genes were filtered unless implied in genomic inversion or eversion; 3) predictions related to ribosomal proteins or small nuclear ribosomal proteins were removed.

Fusion gene validation {#s4_7}
----------------------

Selected fusion transcripts were subjected to validation using RT-PCR and Sanger sequencing. For the RT-PCR reactions, total RNA was converted to cDNA with random hexamer primers using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). The RT-PCR products were gel purified and sequenced by Sanger sequencing using an ABI 3730 DNA Sequencer (Applied Biosystems, Foster City, CA, USA).

5′ RACE and 3′ RACE {#s4_8}
-------------------

5′ RACE. RLM-RACE was performed with the SMARTer™ RACE cDNA Amplification Kit (Clontech). Total RNA (10 mg) was first treated with calf intestinal alkaline phosphatase (CIP) to remove 5′ phosphate groups, followed by tobacco acid pyrophosphatase to remove 5′ cap structures. After RNA linker ligation, mRNA transcripts were reverse-transcribed with SMARTScribe™ reverse transcriptase. To amplify first-strand cDNAs, we performed NEST PCR. Firstly, outer 5′ PCR using 5′ RACE outer primers (provided in kit) and a *IFT88* intron 15 primer (TAGGGAATGACAGGAAACGGGGAT) with SuperTaq Plus polymerase (Applied Biosystems). Subsequently, inner 5′ PCR was performed with a 5′ RACE inner primer (provided in kit) and a *CYRL1* exon 3 primer (TTCCA CACTCAGGGAGCCTTTCA). After gel electrophoresis, PCR bands of interest were excised and cloned. The PCR production were sequenced bidirectionally on an ABI 3730 automated sequencer (Applied Biosystems). A minimum of 3 independent colonies were sequenced in each experiment.

3′ RACE {#s4_9}
-------

RLM-RACE was performed with the SMARTer™ RACE cDNA Amplification Kit (Clontech). Total RNA (10 mg) was first treated with calf intestinal alkaline phosphatase (CIP) to remove 3′ phosphate groups, followed by tobacco acid pyrophosphatase to remove 3′ cap structures. After RNA linker ligation, mRNA transcripts were reverse-transcribed with SMARTScribe™ reverse transcriptase. To amplify first-strand cDNAs, we performed NEST PCR, firstly, outer 3′ PCR using 3′ RACE outer primers (provided in kit) and a *CYRL1* exon 2 primer (GAGGCTTCCAGGTGAAACTCTATGA) with SuperTaq Plus polymerase (Applied Biosystems). Subsequently, inner 3′ PCR was performed with a 3′ RACE inner primer (provided in kit) and a *IFT88* intron 15 primer (TTATCC CCGTTTCCTGTCATTCCCT). After gel electrophoresis, PCR bands of interest were excised and cloned. The PCR production were sequenced bidirectionally on an ABI 3730 automated sequencer (Applied Biosystems). A minimum of 3 independent colonies were sequenced in each experiment.
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HCC

:   (hepatocellular carcinoma)

DEGs

:   (differentially expressed genes) RACE (Rapid-Amplification of cDNA Ends)

RLM-RACE

:   (RNA Ligase-Mediated-Rapid Amplification of cDNA Ends)

FL-HCC

:   (fibrolamellar hepatocellular carcinoma)

GO enrichment analyses

:   (Gene Ontology-based statistical enrichment analysis)

FDR

:   (false discovery rate)

IGV

:   (Integrative Genomics Viewer)

CD-search

:   (Conserved Domains search)

ORF

:   (open reading frame)

NAD

:   (Nicotinamide adenine dinucleotide)

TPR

:   (tetratrico peptide repeat)

HBV

:   (Hepatitis B virus)

HBsAg

:   (HB surface antigen)

HCV

:   (Hepatitis C virus)

NBNC tumor

:   (non-B non-C tumor)

FPKM

:   (fragments per kilobase per million)

CIP

:   (calf intestinal alkaline phosphatase)

CRYL1

:   (crystallin, lambda 1)

IFT88

:   (intraflagellar transport 88)

BRD9

:   (bromodomain containing 9)

OR4N2

:   (olfactory receptor, family 4, subfamily N, member 2)

MPV17

:   (MpV17 mitochondrial inner membrane protein)

TRIM54

:   (tripartite motif containing 54)

BHMT

:   (betaine-homocysteine S-methyltransferase)

MTATP6P1

:   (mitochondrially encoded ATP synthase 6 pseudogene 1)

NOMO3

:   (NODAL modulator 3)

XYLT1

:   (xylosyltransferase I)

TNFSF14

:   (tumor necrosis factor (ligand) superfamily, member 14)

C3

:   (complement component 3)
